A synthetic stable pentadecapeptide derived from a protein in gastric juice, researched mainly for soft-tissue (tendon, ligament, muscle), gut and wound healing.
Research use only — not approved by FDA or EMA for any indication. The FDA placed it in Category 2 (2023), barring compounding pharmacies from using it for lack of safety data. Banned in sport by WADA since January 2022.
Also known as: Body Protection Compound 157, PL 14736, Bepecin
Promotes angiogenesis by upregulating VEGF and the VEGFR2-Akt-eNOS nitric-oxide pathway to build new blood vessels at injury sites. Stimulates fibroblast growth and migration via the FAK-paxillin pathway, accelerates collagen remodelling, and is cytoprotective and anti-inflammatory through the nitric-oxide system. Also interacts with dopaminergic, serotonergic and growth-hormone signalling.
The impressive evidence is almost entirely rodent work — tendon, ligament, gut and CNS injury models — much of it from a single research group, which is a real limitation. Human data are extremely thin: fewer than about 30 people across published reports, with no completed randomised placebo-controlled efficacy trial. Published human work is limited to a small IV safety pilot, case reports and uncontrolled observational series. A 2025 systematic review of 36 papers (1993-2024) found only one clinical study among them. Promising in animals, essentially untranslated in humans.
We report both positive and negative trial results. For exact study protocols, read the sources — we cite them rather than repackage them.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
Human adverse-effect data are largely uncharacterised because rigorous trials are absent. A small IV pilot reported no serious adverse events, but that cannot establish a safety profile. Long-term safety, immunogenicity and effects of chronic use are unknown.
TB-500 / Thymosin Beta-4 — the classic pairing, both marketed for soft-tissue repair with claimed complementary angiogenic and cytoprotective actions. GHK-Cu — shared regenerative positioning. Be aware: these pairings are marketing conventions, not validated combination therapies.
Mechanistic context only — we don't publish combinations, amounts or protocols.
Its closest analogue is TB-500. Both are sold for tissue healing, but thymosin beta-4 has at least reached formal ophthalmic phase 2/3 trials in its full-length form, whereas BPC-157 has essentially no controlled human efficacy data at all.
No. The tendon-healing evidence comes from rodent studies; there is no completed controlled human trial demonstrating it.
A common misconception. It is a synthetic sequence said to be derived from a gastric protein — it is not a naturally occurring isolated human peptide.
No. Because it has no regulatory approval it is ineligible for a WADA Therapeutic Use Exemption and can trigger sanctions.
No reviews yet. If you've used BPC-157, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.